Public trust fractures when a healer becomes a merchant. In the bustling clinics of Karachi and Lahore, a transaction often occurs that has nothing to do with patient recovery and everything to do with profit. Pharmaceutical representatives slide across desks, offering renovations, travel packages, and cash in exchange for prescriptions. These are not isolated incidents of bad judgment. They are gears in a massive, hidden engine of corruption that drives up healthcare costs for the country’s poorest citizens. Mishal Khan, a professor at the London School of Hygiene and Tropical Medicine, decided to look where others turned away. She scrutinized this machinery of bribery, armed with audacity and a novel scientific strategy.
Khan grew tired of the polite silence surrounding medical corruption in Pakistan. Traditional research methods often fail to capture illicit behaviors because people rarely admit to wrongdoing on standard questionnaires. To penetrate this wall of secrecy, Khan developed a methodology that bypassed self-reporting entirely. She employed “mystery shoppers”—actors trained to pose as patients or observers—to observe firsthand the interactions between doctors and pharmaceutical agents. Her work ripped the veil off a system where clinical decisions are often compromised by commercial pressure.
Unmasking The Shadow Economy
The study required immense precision. Sending observers into private clinics involved risk, yet it provided the only unfiltered view of the dynamic between physicians and the industry. Khan’s team documented instances where pharmaceutical agents promised clinic renovations or expensive equipment. These were not vague assurances. They were direct quid pro quo arrangements. If a doctor prescribed a specific volume of a drug, they received a financial reward. The data revealed a normalizing of bribery that shocked even seasoned public health officials.
Current regulations in Pakistan offer little resistance to these practices. The pharmaceutical sector operates with minimal oversight, allowing companies to aggressively incentivize doctors. Khan’s research exposed how these incentives distort medical advice. Patients, often unaware of the financial currents swirling around them, receive prescriptions based on which company offered the doctor the best perk, rather than which medicine offers the best cure. “We are seeing the commercialization of healthcare leading to profits being prioritized over patients,” Khan observes regarding the crisis. Her findings provided irrefutable evidence that the medical profession in the region faces a profound ethical crisis.
A System Built On Incentives
Corruption here is not merely about individual greed. It is structural. Low salaries for medical professionals create a vulnerability that pharmaceutical companies ruthlessly exploit. Khan’s analysis suggests that without addressing the economic realities doctors face, punitive measures alone will fail. The entire ecosystem forces physicians to rely on external income to maintain their clinics and livelihoods. Pharmaceutical companies stepped into this gap, acting as financiers who demand loyalty in the form of prescriptions.
The implications for global health are severe. When profit dictates prescribing habits, it leads to the overuse of medications, contributing to antimicrobial resistance. Khan’s work connects these local acts of bribery to a broader global dysfunction. International aid funders and policymakers often pour money into health systems without understanding these hidden leakages. Her research necessitates a comprehensive reevaluation of how health governance operates in low and middle-income countries. Accountability cannot exist if the primary stakeholders—the doctors and companies—operate in a shadow economy.
The Outsider Breaking Barriers
Mishal Khan has spent her career dismantling obstacles. She arrived at Cambridge University as an outsider, a young woman from a background underrepresented in the elite halls of British academia. Yet, she secured a double first-class degree. At 24, she published a randomized controlled trial in The Lancet, the world’s most prestigious medical journal, before she even held a PhD. Her trajectory defies the slow, plodding pace usually associated with academic advancement. By the time she reached her late thirties, she had achieved the rank of full professor.
Her drive stems from a desire to decolonize the field of global health. Khan argues that lower-income nations must seize control of their health priorities rather than relying on directives from the Global North. She uses her platform to challenge unjust hierarchies and racial biases within the scientific community. The corruption study is part of this larger mission: to strengthen health systems from within by exposing the rot that weakens them. “My goal is to define my personal brand as a trusted, insightful, and outspoken public health scientist,” Khan states, emphasizing her intent to continue challenging the status quo. She proves that rigorous science, when paired with moral courage, can force even the most powerful industries to face the light.